Table 2. Univariate and multivariate analyses of overall survival for each clinicopathological parameter and CPCC.
|
Total |
|||
|---|---|---|---|
| Variable | Group | HR (95% CI) | Pa |
| Gender | Male | 1 | |
| Female | 0.75 (0.52–1.08) | 0.119 | |
| Age, years | <50 | 1 | (<0.001) |
| 50–59 | 0.92 (0.56–1.50) | 0.726 | |
| 60–69 | 1.74 (1.14–2.67) | 0.011 | |
| ⩾70 | 2.59 (1.57–4.28) | <0.001 | |
| Histology (WHO) | WD–MD | 1 | |
| PD | 1.89 (1.32–2.72) | 0.001 | |
| SRC | 0.91 (0.52–1.59) | 0.748 | |
| Others | 2.34 (1.26–4.33) | 0.007 | |
| Lauren classification | Intestinal | 1 | |
| Diffuse | 1.12 (0.79–1.61) | 0.508 | |
| Mixed | 1.07 (0.59–1.93) | 0.828 | |
| Unknown | |||
| Depth of invasion | T1 | 1 | (<0.001) |
| T2 | 2.43 (1.13–5.24) | 0.023 | |
| T3 | 5.60 (3.47–10.36) | <0.001 | |
| T4 | 11.75 (7.13–19.35) | <0.001 | |
| LN metastasis | N0 | 1 | (<0.001) |
| N1 | 2.79 (1.54–5.04) | 0.001 | |
| N2 | 4.43 (2.65–7.43) | <0.001 | |
| N3 | 9.29 (6.11–14.12) | <0.001 | |
| Metastasis | No | 1 | |
| Yes | 7.94 (5.06–12.45) | <0.001 | |
| Tumor locationb | Upper | 1 | |
| Middle | 1.09 (0.61–1.95) | 0.773 | |
| Lower | 0.83 (0.50–1.38) | 0.468 | |
| Overlapping | 3.52 (1.95–6.35) | <0.001 | |
| Tumor size | 1 (⩽3.0 cm) | 1 | (<0.001) |
| 2 (>3.0, ⩽5.0 cm) | 1.77 (0.99–3.17) | 0.054 | |
| 3 (>5.0, ⩽7.0 cm) | 2.34 (1.28–4.27) | 0.006 | |
| 4 (>7.0 cm) | 5.82 (3.37–10.03) | <0.001 | |
| Adjuvant chemotherapy | No | 1 | |
| Yes | 5.45 (3.65–8.13) | <0.001 | |
| CPCC (univariate) | Group 1 (⩽6, N=156) | 1 | (0.188) |
| Group 2 (7–17, N=151) | 0.94 (0.64–1.40) | 0.765 | |
| Group 3 (⩾18, N=130) | 1.30 (0.89–1.89) | 0.178 | |
| CPCC (multivariate)c | Group 1 (⩽6, N=156) | 1 | (0.620) |
| Group 2 (7–17, N=151) | 0.80 (0.52–1.23) | 0.301 | |
| Group 3 (⩾18, N=130) | 0.90 (0.59–1.37) | 0.610 | |
Abbreviations: CI, confidence interval; CPCC, chromatin CKAP2 (cytoskeleton-associated protein 2)-positive cell count; HR, hazard regression; LN, lymph node; MD, moderately differentiated adenocarcinoma; PD, poorly differentiated adenocarcinoma; SRC, signet-ring cell carcinoma; WD, well-differentiated adenocarcinoma; WHO, World Health Organization.
The P-value from the univariate or multivariate analyses is shown. The P-value for the linear trend is shown in parentheses.
The tumor location was classified as follows: upper tumor, tumor located in the upper 1/3 of the stomach; middle tumor, tumor located in the middle 1/3 of the stomach; lower tumor, tumor located in the lower 1/3 of the stomach; overlapping tumor, tumor at the borderline between upper and middle tumors or between middle and lower tumors.
Multivariate analysis with a Cox proportional hazard regression model was used with the co-variables of age, T stage, N stage, histology, tumor location, tumor size, and adjuvant chemotherapy. All patients included in the univariate analysis were also included in the multivariate analysis.
Significant values are shown in bold.